FDA Approves ZYNYZ — Incyte Corporation

# FDA Approves Incyte's ZYNYZ (retifanlimab-dlwr), Expanding the Company's Oncology Portfolio Incyte Corporation announced FDA approval of ZYNYZ (retifanlimab-dlwr), an intravenous immunotherapy, positioning the company to capture additional market share in the competitive immuno-oncology space and potentially driving revenue growth through new treatment indications. The approval strengthens Incyte's pipeline and diversifies its revenue streams beyond its established franchises, though market impact will depend on clinical adoption, pricing strategy, and competitive positioning against existing therap